Call for Papers: International Conference on Nanotechnologies and Biomedical Engineering (ICNBME)

7 - 8 July 2011, Chisinau, Republic of Moldova.
ICNBME-2011 continues the series of International Conferences in the field of nanotechnologies and biomedical engineering. The conference aims at bringing together scientists and engineers dealing with fundamental and applied research for reporting on the latest theoretical developments and applications in the fields involved.

Contributing papers are called in the following areas:

  • Nanotechnologies and Nanomaterials;
  • Micro- and Nano-objects, Nanostructured and highly integrated systems, Biophysics;
  • Plasmonics and Metamaterials;
  • Biomedical Optics and Lasers;
  • Sensors and Transducers;
  • Terahertz spectroscopy;
  • Biomedical Instrumentation and Devices;
  • Health Care Management;
  • Medical Imaging, Image and Signal Processing;
  • Radiation Protection and Dosymetry, Biological Effect of Radiation;
  • Biomedical Engineering Education;
  • Information Technologies for Health Care, Telemedicine and E-Health;
  • Other topics in biomedical engineering.

Submission of Papers
Contributed papers should be subscribed on four-six pages and submitted by e-mail in Microsoft Word format to This email address is being protected from spambots. You need JavaScript enabled to view it.

Accepted papers will be included in the Conference Proceedings, distributed to the participants at the beginning of the conference.

Deadlines:

  • May 1 st, 2011 - Submission of extended abstracts
  • May 15th, 2011 - Notification of acceptance
  • June 15th, 2011 - Advanced Conference Registration
  • June 20th, 2011 - Hotel/trip reservation
  • July 1th, 2011 --Deadline for Registration Fee refunding
  • July 5-6th, 2011 - Arrival and Registration of Participants
  • July 7th, 2011 - Opening of the Conference
  • July 9 th, 2011 - Social Program
  • July 9-10th, 2011 - Departure of Participants

For further information and registration, please visit:
http://www.icnbme.sibm.md

Most Popular Now

Cancer cells are quick-change artists adapting to …

Until now, researchers have assumed that the growth of solid tumors originates from cancer stem cells characterized by specific surface markers, which develop in a fixed...

Nucala (mepolizumab) gains FDA approval for two ne…

GlaxoSmithKline (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) has approved two new methods for administering Nucala (mepolizumab), an autoinjec...

Jeff Settleman, Ph.D., joins Pfizer to lead Oncolo…

Pfizer Inc. (NYSE: PFE) announced that Jeff Settleman, Ph.D., will join the company as Senior Vice President and Group Head of Oncology Research & Development, leading al...

Full data from CAROLINA® outcome trial support lon…

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced full data from the CAROLINA® trial demonstrating that Trajenta® (linagliptin) did not increase cardio...

Cannabis use among older adults rising rapidly

Cannabis use among older adults is growing faster than any other age group but many report barriers to getting medical marijuana, a lack of communication with their docto...

Cleveland researchers test novel gene therapy for …

A novel gene therapy clinical trial at University Hospitals Seidman Cancer Center and the Case Comprehensive Cancer Center is showing promising results, garnering funding...

Merck pioneers new effort to see MS from the insid…

Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple ...

Bristol-Myers Squibb announces post-closing leader…

Bristol-Myers Squibb Company (NYSE:BMY) today announced the future leadership team of the combined company effective upon completion of the company’s pending merger with ...

Novartis Kisqali significantly extends life in wom…

Novartis announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy[1]. The Phase 3 MONALEESA-7 trial evaluated K...

Amgen joins with community oncology networks for n…

Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiat...

Bayer receives U.S. FDA breakthrough therapy desig…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib (Aliqopa™) for the treatment of adult patie...

Prescription drug costs steadily soar, yet price t…

After reviewing tens of millions of insurance claims for the country’s 49 most popular brand-name prescription drugs, a team from Scripps Research Translational Institute...